RECURRENT PRIMARY PERITONEAL CLEAR CELL ADENOCARCINOMA
Clinical trials for RECURRENT PRIMARY PERITONEAL CLEAR CELL ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT PRIMARY PERITONEAL CLEAR CELL ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT PRIMARY PERITONEAL CLEAR CELL ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New vaccine combo aims to outsmart recurrent ovarian cancer
Disease control Recruiting nowThis study tests a new treatment for ovarian cancer that has returned after initial therapy. It combines a personalized vaccine made from a patient's own white blood cells (FRalphaDC) with an immunotherapy drug (pembrolizumab). The goal is to safely boost the immune system to rec…
Matched conditions: RECURRENT PRIMARY PERITONEAL CLEAR CELL ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 26, 2026 04:23 UTC
-
New drug cocktail aims to shrink ovarian tumors in recurrent cancer
Disease control Recruiting nowThis study tests whether adding an experimental drug (CDX-1140) to a standard immunotherapy combo (pembrolizumab and bevacizumab) can shrink tumors in people with ovarian cancer that has returned. About 80 adults with recurrent ovarian, fallopian tube, or peritoneal cancer will r…
Matched conditions: RECURRENT PRIMARY PERITONEAL CLEAR CELL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated May 26, 2026 04:21 UTC